# **Investor Presentation**

Third Quarter 2013




# **Experience.** Redefined.

Statements in this presentation that are not historical in nature, including those concerning the Company's current expectations about its future requirements and needs, are "forward-looking" statements as defined in Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by words such as "may," "should," "expects," "provides," "anticipates," "assumes," "can," "will," "meets," "could," "likely," "intends," "might," "predicts," "seeks," "would," "believes," "estimates," "plans" or "continues." These forward-looking statements reflect our current expectations about our future requirements and needs, results, levels of activity, performance, or achievements, including, without limitation, current expectations with respect to, among other factors, utilization rates, billing rates, and the number of revenue-generating professionals; that we are able to expand our service offerings; that we successfully integrate the businesses we acquire; and that existing market conditions continue to trend upward. These statements involve known and unknown risks, uncertainties and other factors, including, among others, those described under "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2012 that may cause actual results, levels of activity, performance or achievements to be materially different from any anticipated results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We disclaim any obligation to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.



# **Huron Operating Segments**



Note: Segment percentages are based on year-to-date 2013 revenue results. See the Company's website for additional information.



### **Huron Healthcare**

### **Business Drivers**

transition from fee-for-service to value-based care

post-reform alignment among physicians and providers

intense pressure to reduce cost

declining reimbursement

enhanced quality of care - focus on outcomes and quality measures

### **Clients We Serve**

hospitals

health systems

academic medical centers

physician groups





# **Huron Legal**

### **Business Drivers**

strong incentive to reduce corporate legal costs and related litigation and investigation expenses

proliferation of electronic documents

complex regulatory challenges

increased use of technology to support discovery and matter management

#### **Clients We Serve**

global 1,000 companies

Am Law 100

leading European law firms





## **Huron Education**

### **Business Drivers**

decreased public financial support

research funding has flattened

rapidly expanding on-line learning platform

competing in global arena for brand and students

lack of revenue growth due to tuition pricing pressure

### **Clients We Serve**

colleges and universities

research institutions

academic medical centers





## **Huron Life Sciences**

### **Business Drivers**

increasing global regulations demanding greater transparency

escalating research costs leading to more outsourcing

expiring patents, generic competition, and slow pipeline development creating more M&A


growing need for compliance and business integration services

#### **Clients We Serve**

pharmaceutical companies

medical device manufacturers

law firms





## **Huron Financial**

#### **Business Drivers**

distressed industries or underperforming companies

debt or equity transactions

turnaround situations, M&A activity, bankruptcies, disputes or litigation

interim management needs: CEO, CFO, CRO

advice to executive management and boards of directors facing complex situations

#### **Clients We Serve**

provide a flexible service model: serving large corporations or middle market clients, law firms, investment banks, lenders & private equity






# **Financial Overview**



## **Growth Track Record**


Revenues from Continuing Operations (in millions)





## **Growth Track Record**

### Adjusted EBITDA (in millions) and Adjusted EBITDA Margins




See accompanying appendix for a reconciliation of Adjusted EBITDA, which is a non-GAAP measure, to the most comparable GAAP measure.



## **Growth Track Record**

### Adjusted Diluted Earnings Per Share




See accompanying appendix for a reconciliation of Adjusted Diluted Earnings Per Share, which is a non-GAAP measure, to the most comparable GAAP measure.



### **Free Cash Flow**

#### Free Cash Flow Per Share & Free Cash Flow Yield



Free cash flow is defined as cash from operations minus capital expenditures. Free cash flow yield is defined as free cash flow per share divided by end of period stock price.

See accompanying appendix for a reconciliation of free cash flow, which is a non-GAAP measure, to the most comparable GAAP measure.



# **Operating Metrics**

### **Operating Metrics From Continuing Operations**

	2008	2009	2010	2011	2012
Number of Full-Time Billable Consultants	1,109	1,071	1,108	1,275	1,472
Headcount Leverage (1)	9.6	9.3	9.9	11.1	14.5
Full-Time Billable Consultant Utilization Rate	73.5%	72.0%	73.6%	75.1%	75.4%
Average Full-Time Equivalents	650	743	900	1,134	1,145
Revenue Per Day (in thousands)	\$2,211	\$2,176	\$2,173	\$2,539	\$2,631

(1) Headcount leverage is the number of non-MD full-time billable consultants divided by the number of MDs at the end of each period.



# **Appendices**

#### **Reconciliations of Non-GAAP Measures to Comparable GAAP Measures**

In evaluating the Company's financial performance, management uses earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted EBITDA, adjusted EBITDA as a percentage of revenues, adjusted net income from continuing operations, adjusted diluted earnings per share from continuing operations, free cash flow per share, and free cash flow yield, which are non-GAAP measures. Our management uses these non-GAAP financial measures to gain an understanding of our comparative operating performance (when comparing such results with previous periods or forecasts). These non-GAAP financial measures are used by management in their financial and operating decision making because management believes they reflect our ongoing business in a manner that allows for meaningful period-to-period comparisons. Management also uses these non-GAAP financial measures when publicly providing our business outlook, for internal management purposes, and as a basis for evaluating potential acquisitions and dispositions. We believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating Huron's current operating performance and future prospects in the same manner as management does, if they so choose, and in comparing in a consistent manner Huron's current financial results with Huron's past financial results, Investors should recognize that these non-GAAP measures might not be comparable to similarly titled measures of other companies. These measures should be considered in addition to, and not as a substitute for or superior to, any measure of performance, cash flows or liquidity prepared in accordance with accounting principles generally accepted in the United States.



## **Reconciliations of Non-GAAP Measures**

Reconciliation of Net Income from Continuing Operations to Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (in millions)

	2007	2008	2009	2010	2011	2012	3Q12 YTD	3Q13 YTD
Revenues	\$315	\$430	\$526	\$516	\$606	\$626	\$445	\$509
Net Income From Continuing Operations	\$(10)	\$(1)	\$14	\$7	\$21	\$36	\$17	\$44
Add Back:								
Income Tax Expense	6	15	19	13	22	30	16	34
Interest & Other Expenses	8	17	10	14	12	8	6	5
Depreciation & Amortization	23	27	26	22	24	22	17	17
EBITDA	27	57	69	57	79	96	56	100
Add Back:								
Non-Cash Compensation	13	15	6	**************************************	-	<b>;=</b> ):	2	
Restatement Related Expenses	-		17	9	5	2	2	
Restructuring Charges	-	2	2	4	4	4	3	
Goodwill Impairment	-	-	8	-	22	13	13	
Litigation Settlements (other gain)	-	n=	(3)	17	1	1	1	(6)
Adjusted EBITDA	\$39	\$74	\$100	\$87	\$111	\$116	\$75	\$94
Adjusted EBITDA %	12.5%	17.3%	18.9%	16.9%	18.3%	18.5%	16.8%	18.4%



## **Reconciliations of Non-GAAP Measures**

Reconciliation of Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations (in millions)

	2007	2008	2009	2010	2011	2012	3Q12 YTD	3Q13 YTD
Net Income (Loss) From Continuing Operations	\$(10)	\$(1)	\$14	\$7	\$21	\$36	\$17	\$44
Weighted Average Shares	17	18	21	21	22	22	22	23
Diluted Earnings (loss) Per Share (EPS)	\$(0.61)	\$(0.07)	\$0.66	\$0.36	\$0.99	\$1.61	\$0.78	\$1.95
Add Back:								
Amortization of Intangible Assets	12	12	9	8	8	7	5	4
Non-Cash Compensation	13	15	6	-	=	-	2	
Restatement Related Expenses	-	-	17	9	5	2	2	
Restructuring Charges	-	2	2	-	22	13	3	
Goodwill Impairment	*		8	4	4	4	13	
Litigation Settlements (other gain)	(*)	100	(3)	17	1	1	1	(6)
Tax Effect	(5)	(6)	(14)	(15)	(15)	(11)	(10)	
Total Adjustments, Net of Tax	20	23	26	23	24	16	15	(1)
Adjusted Net Income From Continuing Operations	\$10	\$22	\$40	\$30	\$46	\$52	\$32	\$43
Weighted Average Shares	18	19	21	21	22	22	22	23
Adjusted Diluted EPS From Continuing Operations	\$0.54	\$1.16	\$1.93	\$1.45	\$2.11	\$2.34	\$1.44	\$1.91



## **Reconciliations of Non-GAAP Measures**

### Reconciliation of Cash from Operating Activities to Free Cash Flow (in millions)

	2008	2009	2010	2011	2012
Cash from Operations	\$101	\$114	\$50	\$109	\$106
Less Capital Expenditures	(20)	(13)	(9)	(14)	(21)
Free Cash Flow	\$81	\$101	\$42	\$95	\$85
Diluted Shares	19	21	21	22	22
Free Cash Flow Per Share	\$4.26	\$4.94	\$2.00	\$4.37	\$3.81
End of Period Stock Price	\$57.27	\$23.04	\$26.45	\$38.74	\$33.69
Free Cash Flow Yield	7.4%	21.4%	7.6%	11.3%	11.3%



# **Huron: A Closer Look**



## **Fast Facts**

\$625M+ revenue

2,283 full-time employees

1,417 billable consultants

800 client engagements

### serving:

- 90 of the top 100 research organizations
- 400 general counsel
- 385 hospitals and medical centers

15+ global offices/document review centers

NASDAQ Global Select Market / HURN





# **Huron Recognition**



The Chicago Tribune 2013



Modern Healthcare 2013



Consulting 2013, 2012 & 2011



Turnarounds & Workouts 2012



University Business 2012



The Oregonian 2013



## **Huron Solutions in Detail**

Huron Healthcare	Records & Information Management	Huron Financial		
Clinical Documentation Improvement	Staffing	Capital Advisory		
Clinical Operations	Technology Implementation	Forensics & Litigation		
Human Resources	Huron Education	Operational Improvement Restructuring & Turnaround Valuation		
Labor	Strategic Solutions			
Non-Labor	University Performance Improvement			
Physician	Solutions	Huron Software		
Revenue Cycle	Research Enterprise Solutions			
Chrotogu	Technology Solutions	Click® Portal Solutions		
Strategy		ecrt®		
Huron Legal	Huron Life Sciences	efacs™		
Discovery	Pharmaceutical & Medical Device Solutions	Huron Technology		
Law Department Management				
Law Firm Strategy & Management	Research Enterprise Business & Software Solutions	Blue Stone		



# **Huron Leadership**



Jim Roth
Chief Executive Officer
& President



**Diane Ratekin**EVP, General Counsel
& Corporate Secretary



Mark Hussey
EVP, Chief Financial Officer
& Treasurer



Gordon Mountford EVP, Huron Healthcare



**Bob Rowe** EVP, Huron Legal



Laura Yaeger EVP, Huron Education & Life Sciences



John DiDonato Managing Director, Huron Financial



# **Experience.** Redefined.

